The new clearance enables U.S. marketing for percutaneous procedures using computed tomography (CT) optical navigation. These include biopsies and ablations for diagnosing and treating conditions in the chest, abdomen and musculoskeletal structures.
Interventional Systems said the clearance makes Micromate the first needle-based intervention robot available in the U.S. with compatibility for both fluoroscopy and CT. The system first received clearance as a table-mounted medical robot for interventional procedures in June 2021. The company touted it as the world’s smallest robot for those of the percutaneous kind.
Micromate uses cone-beam computed tomography (CBCT), fluoro CT or a fluoroscope for percutaneous needle intervention. It also received clearance for integration into third-party navigation stations.